Skip Nav Destination
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
Issue Archive
March 3 2016
Table of Contents
ANNIVERSARY EDITORIAL
BLOOD FLASHBACK
INSIDE BLOOD COMMENTARIES
PLENARY PAPER
BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Clinical Trials & Observations
Valeria Magarotto,Sara Bringhen,Massimo Offidani,Giulia Benevolo,Francesca Patriarca,Roberto Mina,Antonietta Pia Falcone,Lorenzo De Paoli,Giuseppe Pietrantuono,Silvia Gentili,Caterina Musolino,Nicola Giuliani,Annalisa Bernardini,Concetta Conticello,Stefano Pulini,Giovannino Ciccone,Vladimír Maisnar,Marina Ruggeri,Renato Zambello,Tommasina Guglielmelli,Antonio Ledda,Anna Marina Liberati,Vittorio Montefusco,Roman Hajek,Mario Boccadoro,Antonio Palumbo
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
Clinical Trials & Observations
Sonja Zweegman,Bronno van der Holt,Ulf-Henrik Mellqvist,Morten Salomo,Gerard M. J. Bos,Mark-David Levin,Heleen Visser-Wisselaar,Markus Hansson,Annette W. G. van der Velden,Wendy Deenik,Astrid Gruber,Juleon L. L. M. Coenen,Torben Plesner,Saskia K. Klein,Bea C. Tanis,Damian L. Szatkowski,Rolf E. Brouwer,Matthijs Westerman,M. (Rineke) B. L. Leys,Harm A. M. Sinnige,Einar Haukås,Klaas G. van der Hem,Marc F. Durian,E. (Vera) J. M. Mattijssen,Niels W. C. J. van de Donk,Marian J. P. L. Stevens-Kroef,Pieter Sonneveld,Anders Waage
IMMUNOBIOLOGY
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Clinical Trials & Observations
Joseph A. Fraietta,Kyle A. Beckwith,Prachi R. Patel,Marco Ruella,Zhaohui Zheng,David M. Barrett,Simon F. Lacey,Jan Joseph Melenhorst,Shannon E. McGettigan,Danielle R. Cook,Changfeng Zhang,Jun Xu,Priscilla Do,Jessica Hulitt,Sagar B. Kudchodkar,Alexandria P. Cogdill,Saar Gill,David L. Porter,Jennifer A. Woyach,Meixiao Long,Amy J. Johnson,Kami Maddocks,Natarajan Muthusamy,Bruce L. Levine,Carl H. June,John C. Byrd,Marcela V. Maus
LYMPHOID NEOPLASIA
Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo
Natalie M. Czuczman,Matthew J. Barth,Juan Gu,Vishala Neppalli,Cory Mavis,Sarah E. Frys,Qiang Hu,Song Liu,Pavel Klener,Petra Vockova,Myron S. Czuczman,Francisco J. Hernandez-Ilizaliturri
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells
Michele Cea,Antonia Cagnetta,Sophia Adamia,Chirag Acharya,Yu-Tzu Tai,Mariateresa Fulciniti,Hiroto Ohguchi,Aditya Munshi,Prakrati Acharya,Manoj K. Bhasin,Lei Zhong,Ruben Carrasco,Fiammetta Monacelli,Alberto Ballestrero,Paul Richardson,Marco Gobbi,Roberto M. Lemoli,Nikhil Munshi,Teru Hideshima,Alessio Nencioni,Dharminder Chauhan,Kenneth C. Anderson
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
Clinical Trials & Observations
Bruno Paiva,María Victoria Mateos,Luis Ignacio Sanchez-Abarca,Noemi Puig,María-Belén Vidriales,Lucía López-Corral,Luis A. Corchete,Miguel T. Hernandez,Joan Bargay,Felipe de Arriba,Javier de la Rubia,Ana-Isabel Teruel,Pilar Giraldo,Laura Rosiñol,Felipe Prosper,Albert Oriol,José Hernández,Graça Esteves,Juan José Lahuerta,Joan Bladé,Jose Antonio Perez-Simon,Jesús F. San Miguel,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups,on behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups
MYELOID NEOPLASIA
LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia
Hetty H. Helsmoortel,Silvia Bresolin,Tim Lammens,Hélène Cavé,Peter Noellke,Aurélie Caye,Farzaneh Ghazavi,Andrica de Vries,Henrik Hasle,Veerle Labarque,Riccardo Masetti,Jan Stary,Marry M. van den Heuvel-Eibrink,Jan Philippé,Nadine Van Roy,Yves Benoit,Frank Speleman,Charlotte Niemeyer,Christian Flotho,Giuseppe Basso,Geertruy te Kronnie,Pieter Van Vlierberghe,Barbara De Moerloose
Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction
Sagar Uttarkar,Emilie Dassé,Anna Coulibaly,Simone Steinmann,Anke Jakobs,Caroline Schomburg,Amke Trentmann,Joachim Jose,Peter Schlenke,Wolfgang E. Berdel,Thomas J. Schmidt,Carsten Müller-Tidow,Jon Frampton,Karl-Heinz Klempnauer
PLATELETS AND THROMBOPOIESIS
THROMBOSIS AND HEMOSTASIS
von Willebrand factor is dimerized by protein disulfide isomerase
Svenja Lippok,Katra Kolšek,Achim Löf,Dennis Eggert,Willem Vanderlinden,Jochen P. Müller,Gesa König,Tobias Obser,Karoline Röhrs,Sonja Schneppenheim,Ulrich Budde,Carsten Baldauf,Camilo Aponte-Santamaría,Frauke Gräter,Reinhard Schneppenheim,Joachim O. Rädler,Maria A. Brehm
A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria
Niamh O’Regan,Kristina Gegenbauer,Jamie M. O’Sullivan,Sanaz Maleki,Teresa M. Brophy,Niall Dalton,Alain Chion,Padraic G. Fallon,Georges E. Grau,Ulrich Budde,Owen P. Smith,Alister G. Craig,Roger J. S. Preston,James S. O’Donnell
TRANSPLANTATION
LETTERS TO BLOOD
BLOOD WORK
ERRATA
-
Cover Image
Cover Image
![issue cover]()
Endogenous von Willebrand factor (VWF) and protein disulfide isomerase A1 (PDIA1) were detected in human umbilical vein endothelial cells by indirect immunofluorescence using rabbit anti-VWF plus goat anti-rabbit Alexa Fluor 488 (shown in green) and mouse anti-PDIA1 plus goat anti-mouse Alexa Fluor 647 (shown in red), respectively. Colocalization is shown in yellow. See the article by Lippok et al on page 1183.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
